CSC's DVC And Baxter Begin Phase 1 Clinical Trial For Chemical Defense Product

... Computer Sciences Corporation (NYSE: CSC) today announced that DynPort Vaccine Company LLC (DVC), a CSC company, in conjunction with Baxter Healthcare Corporation, has initiated a Phase 1 clinical trial for plasma-derived butyrylcholinesterase, or "BioScavenger," which is being developed to prevent and possibly treat effects of exposure to certain chemical nerve agents. [click link for full article] ...